A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas
Summary
This clinical study will evaluate the safety, tolerability, and reactogenicity of 2 dose levels of messenger RNA (mRNA)-1893 Zika vaccine in comparison to a placebo control in healthy participants who are flavivirus-seronegative and in participants who are flavivirus-seropositive.
Timeline
- Start
- 2021-06-07
- Primary completion
- 2024-07-26
- Completion
- 2024-07-26
Outcome
Met primary endpoint
registry analysis (other test); Placebo vs mRNA-1893 Low Dose (2-Dose Regimen); Geometric Mean Ratio (GMR) 7.002 (95% CI 5.451 to 8.992) NCT04917861 ↗
registry analysis (other test); Placebo vs mRNA-1893 High Dose (2-Dose Regimen); GMR 7.123 (95% CI 5.467 to 9.279) NCT04917861 ↗
registry analysis (other test); Placebo vs mRNA-1893 Low Dose (2-Dose Regimen); percentage difference 76.69 (95% CI 69.10 to 82.68) NCT04917861 ↗
registry analysis (other test); Placebo vs mRNA-1893 Low Dose (2-Dose Regimen); percentage difference 75.46 (95% CI 68.12 to 81.49) NCT04917861 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | mRNA-1893 | Messenger RNA (mRNA) | — | — |